NYU LANGONE HEALTH
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1841-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.nyulangone.org
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
- Conditions
- Interventions
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 31
- Registration Number
- NCT00483327
- Locations
- 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸NYU Cancer Center, New York, New York, United States
Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
- Conditions
- Interventions
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 9
- Registration Number
- NCT00483119
- Locations
- 🇺🇸
NYU Medical Center, New York, New York, United States
Hirschsprung Disease Genetic Study
- Conditions
- Interventions
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 3000
- Registration Number
- NCT00478712
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall
- Conditions
- Interventions
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 62
- Registration Number
- NCT00468143
- Locations
- 🇺🇸
VANYHHS, New York, New York, United States
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 24
- Registration Number
- NCT00463840
- Locations
- 🇺🇸
NYU Cancer Institute, New York, New York, United States
🇺🇸Bellevue Hospital, New York, New York, United States
Preventive IVIG Therapy for Congenital Heart Block
- Conditions
- Interventions
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 20
- Registration Number
- NCT00460928
- Locations
- 🇺🇸
Saint Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸New York University School of Medicine / NYU-Hospital for Joint Diseases, New York, New York, United States
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 36
- Registration Number
- NCT00444678
- Locations
- 🇺🇸
New York University Langone Medical Center, New York, New York, United States
🇺🇸Bellevue Hospital, New York, New York, United States
Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 30
- Registration Number
- NCT00418132
- Locations
- 🇺🇸
New York University School of Medicine General Clinical Research Center, Bellevue Hospital, New York, New York, United States
Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 43
- Registration Number
- NCT00412841
- Locations
- 🇺🇸
The New York University Hospital For Joint Diseases, New York, New York, United States
NYU/Bellevue WTC Health Impacts Research Registry
- Conditions
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 16000
- Registration Number
- NCT00404898
- Locations
- 🇺🇸
NYU School of Medicine/Bellevue Hospital, New York, New York, United States